Bacteria and other pathogens have always evolved to resist the new drugs that modern medicine uses to combat them. But in recent years the rise in drug resistance has been a particular worry, especially the emergence of antibiotic-resistant superbugs.
Tackling Antibiotic Resistance is now recognised at a national and global level. Reflected in the list of organisations and initiatives outlined below:
- US Presidents’ Council of Advisers on Science & Technology report on Combating Antibiotic Resistance
- Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)
- BEAM Alliance (EU SMEs in Anti-infective drug development)
- The Transatlantic Task Force on Antimicrobial Resistance (TATFAR)
- WHO Global Action Plan on AMR – endorsed at the 68th World Health Assembly
- US National Institute for Allergies and Infectious Diseases (NIAID)
- UK Independent Review on Antimicrobial Resistance (IRAR)
- EU Innovative Medicines Initiative (IMI)
- European & Developing Countries Clinical Trials Partnership (EDCTP)
- US Biomedical Advanced Research and Development Authority (BARDA)
- Antibiotic Resistance is now on the G7, G8 & G20 agendas
The XF Drugs represent a new breed of antibacterial drug product, which due to their unique features will operate within existing antibiotic markets but also open new preventative and therapeutic drug markets that are closed to traditional antibiotics because of the existence and/or threat of AR.
Destiny Pharma’s lead product exeporfinium chloride (XF-73) focuses
on addressing the burden caused by one of the major Gram positive bacteria,
Staphylococcus aureus, a leading world cause of post-surgical
infection. S. aureus and its better known AR version, MRSA are
a major cause of morbidity, mortality and cost to global healthcare
Destiny Pharma’s XF drug pipeline includes a number of follow-on therapeutic and preventative medicines.
“Catastrophic threat” posed by antibiotic resistant bacteria
Dame Sally Davies, the UK’s Chief medical officer has said
that antibiotic-resistant diseases pose ‘apocalyptic’ threat, whilst
the UK’s ex-Chancellor George Osbourne has warned of the global threat
of antibiotic resistance which failure to act could cast healthcare
back into the dark ages of medicine where treatable infections and
injuries will kill once again.